文献速递瓣膜病与结构性心脏病血脂与心血管预防

脂蛋白(a)浓度与生物瓣主动脉瓣退变的相关性

Role of lipoprotein(a) concentrations in bioprosthetic aortic valve degeneration.
PubMed 文献 · Heart · 2024-01-29

这项回顾性多中心研究纳入210例2010至2020年间接受生物瓣主动脉瓣置换且有Lp(a)检测的患者,随访超声评估瓣膜退变。随访中33例(15.7%)出现退变,退变者Lp(a)中位数显著更高(50.0 vs 15.6 mg/dL,p=0.002)。高Lp(a)(≥30 mg/dL)在多变量分析中与退变独立相关(HR 4.4,95%CI 1.9-10.4,p=0.001)。

要点

  • 生物瓣主动脉瓣置换后随访4.4年,15.7%患者出现瓣膜退变。
  • 瓣膜退变者Lp(a)中位数50.0 mg/dL,显著高于无退变者的15.6 mg/dL。
  • Lp(a)≥30 mg/dL与生物瓣退变独立相关,校正后HR 4.4。

核心结论

  • 高血清Lp(a)水平与生物瓣主动脉瓣退变相关。

主要发现

  • 随访超声中位时间4.4年(IQR 3.7),33例(15.7%)出现生物瓣退变。
  • 退变患者Lp(a)中位数50.0 mg/dL(IQR 72.0),无退变患者15.6 mg/dL(IQR 48.6),p=0.002。
  • 单变量分析中Lp(a)≥30 mg/dL与退变相关(HR 3.6,95%CI 1.7-7.6,p=0.001)。
  • 多变量分析校正其他退变危险因素后,Lp(a)≥30 mg/dL仍与退变相关(HR 4.4,95%CI 1.9-10.4,p=0.001)。

关键数值与推荐

  • 生物瓣退变定义为平均跨瓣压差较基线增加>10 mm Hg并伴有效瓣口面积和Doppler速度指数下降,或新出现中/重度人工瓣膜反流。
  • 高Lp(a)水平定义为≥30 mg/dL。

临床怎么用

  • 对于接受生物瓣主动脉瓣置换的患者,可考虑检测Lp(a)水平以辅助评估瓣膜退变风险。
  • 高Lp(a)(≥30 mg/dL)患者可能需要更密切的超声随访监测瓣膜功能。

局限性

  • 回顾性研究设计可能引入选择偏倚和信息偏倚。
  • 研究未评估降低Lp(a)水平是否能延缓生物瓣退变,需前瞻性研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Lipoprotein(a) (Lp(a)) is associated with an increased incidence of native aortic stenosis, which shares similar pathological mechanisms with bioprosthetic aortic valve (bAV) degeneration. However, evidence regarding the role of Lp(a) concentrations in bAV degeneration is lacking. This study aims to evaluate the association between Lp(a) concentrations and bAV degeneration. METHODS: In this retrospective multicentre study, patients who underwent a bAV replacement between 1 January 2010 and 31 December 2020 and had a Lp(a) measurement were included. Echocardiography follow-up was performed to determine the presence of bioprosthetic valve degeneration, which was defined as an increase >10 mm Hg in mean gradient from baseline with concomitant decrease in effective orifice area and Doppler Velocity Index, or new moderate/severe prosthetic regurgitation. Levels of Lp(a) were compared between patients with and without degeneration and Cox regression analysis was performed to investigate the association between Lp(a) levels and bioprosthetic valve degeneration. RESULTS: In total, 210 cases were included (mean age 74.1±9.4 years, 72.4% males). Median time between baseline and follow-up echocardiography was 4.4 (IQR 3.7) years. Bioprostheses degeneration was observed in 33 (15.7%) patients at follow-up. Median serum levels of Lp(a) were significantly higher in patients affected by degeneration versus non-affected cases: 50.0 (IQR 72.0) vs 15.6 (IQR 48.6) mg/dL, p=0.002. In the regression analysis, high Lp(a) levels (≥30 mg/dL) were associated with degeneration both in a univariable analysis (HR 3.6, 95% CI 1.7 to 7.6, p=0.001) and multivariable analysis adjusted by other risk factors for bioprostheses degeneration (HR 4.4, 95% CI 1.9 to 10.4, p=0.001). CONCLUSIONS: High serum Lp(a) is associated with bAV degeneration. Prospective studies are needed to confirm these findings and to investigate whether lowering Lp(a) levels could slow bioprostheses degradation.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Farina JM, Chao CJ, Pereyra M, et al. Role of lipoprotein(a) concentrations in bioprosthetic aortic valve degeneration. Heart. 2024. PMID: 37643771. doi:10.1136/heartjnl-2023-322987

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。